Karen L. Smith
CIK 1639637 · Chief Medical Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.77M
Companies
12
Total Filings
55
Lifetime Open-Market Net
-$2.68M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNTX | Director | — | $0.59 | — | $0 | 3 | 2026-06-26 |
| SKYE | Director | — | $0.61 | — | $0 | 5 | 2026-04-02 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 102,100 | $0.18 | $18.1K | $0 | 9 | 2025-06-16 |
| AUPH | Director | 24,807 | $14.96 | $371.1K | -$44.2K | 3 | 2024-11-25 |
| Tourmaline Bio, Inc. (TALS) Delisted | Director | — | $27.20 | — | $0 | 3 | 2023-06-14 |
| QNCX | Chief Medical Officer | — | $19.37 | — | $0 | 1 | 2023-02-02 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Chief Medical Officer | 194,690 | $1.95 | $379.6K | $0 | 2 | 2022-05-27 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | -$2.88M | 8 | 2021-11-22 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| EBS | EVP, Chief Medical Officer | 11,888 | $7.31 | $86.9K | $0 | 2 | 2021-05-11 |
| JAZZ | EVP, R&D and CMO | 28,474 | $256.92 | $7.32M | $250.0K | 13 | 2018-03-07 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | — | — | — | $0 | 1 | 2018-02-13 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-05 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +25,000 | $0 | EDGAR |
| 2023-08-21 | AUPH | Grant (A) | — | $0 | EDGAR |
| 2023-06-14 | Tourmaline Bio, Inc. (TALS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +13,900 | $0 | EDGAR |
| 2023-02-02 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | Tourmaline Bio, Inc. (TALS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-27 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | +170,354 | $0 | EDGAR |
| 2022-05-26 | — | Disp (D) | −79,645 | -$446.0K | |
| 2022-05-23 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | +24,336 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.